Skip to content
PeptideAgent

Exenatide regulatory status

Current status of Exenatide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Exenatide?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 27, 2026
FDA and compounding
FDA approved products (Byetta April 2005, Bydureon January 2012, Bydureon BCise October 2017) for type 2 diabetes. Because exenatide is a component of approved drugs, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of a marketed product. Exenatide was not part of the semaglutide and tirzepatide shortage era. Product presentations have narrowed over time; check DailyMed for what is currently marketed.
WADA
Not WADA prohibited
Access path
  1. Prescription from a licensed provider (in person or telehealth) filled at a retail or specialty pharmacy as Byetta or Bydureon BCise.
  2. Not available through compounding pharmacies or telehealth peptide clinics as a compounded product.
  3. Products labeled research use only are not lawful for human use.

Full Exenatide page: evidence, dosing in the literature, and sources

How has the status of Exenatide changed over time?

  1. FDA

    FDA approves Bydureon, once-weekly extended-release exenatide

    FDA approved the extended-release, once-weekly formulation of exenatide (Bydureon) for type 2 diabetes after earlier complete response letters.

    Regulatory: FDA approvedSource: Drugs@FDA: Bydureon (exenatide extended-release) NDA 022200
  2. FDA

    FDA approves Byetta (exenatide), the first GLP-1 receptor agonist

    FDA approved twice-daily exenatide injection (Byetta) as adjunctive therapy for type 2 diabetes, the first GLP-1 receptor agonist to reach the US market.

    Regulatory: FDA approvedSource: Drugs@FDA: Byetta (exenatide) NDA 021773

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Exenatide and the source of each dated event.

  1. [1]FDA prescribing information for Byetta (exenatide) injection, via DailyMedFDA, 2025
  2. [2]FDA prescribing information for Bydureon BCise (exenatide extended-release) injectable suspension, via DailyMedFDA, 2025
  3. [3]WADA Prohibited ListWADA, 2026
  4. [4]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
  5. [5]Drugs@FDA: Bydureon (exenatide extended-release) NDA 022200FDA, 2012
  6. [6]Drugs@FDA: Byetta (exenatide) NDA 021773FDA, 2005